Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers
Preeclampsia is the most frequent pregnancy-related complication worldwide with no cure. While a number of molecular features have emerged, the underlying causal mechanisms behind the disorder remain obscure. Here, we find that increased complex formation between angiotensin II AT1 and bradykinin B2...
Saved in:
Published in: | Cell Vol. 176; no. 1-2; pp. 318 - 333.e19 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
10-01-2019
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Preeclampsia is the most frequent pregnancy-related complication worldwide with no cure. While a number of molecular features have emerged, the underlying causal mechanisms behind the disorder remain obscure. Here, we find that increased complex formation between angiotensin II AT1 and bradykinin B2, two G protein-coupled receptors with opposing effects on blood vessel constriction, triggers symptoms of preeclampsia in pregnant mice. Aberrant heteromerization of AT1-B2 led to exaggerated calcium signaling and high vascular smooth muscle mechanosensitivity, which could explain the onset of preeclampsia symptoms at late-stage pregnancy as mechanical forces increase with fetal mass. AT1-B2 receptor aggregation was inhibited by beta-arrestin-mediated downregulation. Importantly, symptoms of preeclampsia were prevented by transgenic ARRB1 expression or a small-molecule drug. Because AT1-B2 heteromerization was found to occur in human placental biopsies from pregnancies complicated by preeclampsia, specifically targeting AT1-B2 heteromerization and its downstream consequences represents a promising therapeutic approach.
[Display omitted]
•The beta-arrestin-biased agonist, TRV027, targets AT1-B2 and prevents preeclampsia•AT1-B2 enhances the vascular sensitivity to angiotensin II and mechanical stimulation•Increased vascular AT1-B2 in pregnant mice is a sufficient cause for preeclampsia•Transgenic ARRB1 counteracts preeclampsia symptoms by downregulation of AT1-B2
This paper provides a mechanistic understanding of the causes of preeclampsia and uses the newly gained insights to explore treatment for the condition. |
---|---|
ISSN: | 0092-8674 1097-4172 |
DOI: | 10.1016/j.cell.2018.10.050 |